There are 2137 resources available
1013P - PTPN13 inactivation by hepatitis B virus X regulates metabolic reprogramming for hepatocellular carcinoma progression
Presenter: Yongcong Yan
Session: E-Poster Display
Resources:
Abstract
1014TiP - PROOF: A multicenter, open-label, randomized, phase III trial of infigratinib vs gemcitabine + cisplatin in patients with advanced cholangiocarcinoma with FGFR2 gene rearrangements
Presenter: Ghassan Abou-Alfa
Session: E-Poster Display
Resources:
Abstract
1015TiP - Ramucirumab in patients with advanced hepatocellular carcinoma and elevated alpha fetoprotein following a non-sorafenib based systemic therapy: An expansion cohort of the phase III REACH-2 study
Presenter: Richard Finn
Session: E-Poster Display
Resources:
Abstract
1016TiP - LEAP-012 trial in progress: Pembrolizumab plus lenvatinib and transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma (HCC) not amenable to curative treatment
Presenter: Josep Llovet
Session: E-Poster Display
Resources:
Abstract
1017TiP - KEYNOTE-937 trial in progress: adjuvant pembrolizumab in patients with hepatocellular carcinoma (HCC) and complete radiologic response after surgical resection or local ablation
Presenter: Arndt Vogel
Session: E-Poster Display
Resources:
Abstract
1018TiP - ALTER-H-004: A phase II study of anlotinib combined with TACE as adjuvant therapy in hepatocellular carcinoma patients at high risk of post-surgery recurrence
Presenter: Zheng Wu
Session: E-Poster Display
Resources:
Abstract
1028P - Clinical results of a pilot trial of GEN-009, a neoantigen vaccine containing immunogenic tumour specific neoantigens, in combination with PD-1 inhibitors in advanced cancers
Presenter: Maura Gillison
Session: E-Poster Display
Resources:
Abstract
1030P - First-in-human study of camidanlumab tesirine (ADCT-301, Cami), an anti-CD25 targeted therapy in patients (pts) with advanced solid tumours: Pharmacokinetics (PK) and biomarker evaluation
Presenter: Igor Puzanov
Session: E-Poster Display
Resources:
Abstract
1029P - Addition of dendritic cell vaccines to neoadjuvant chemotherapy in HER2 negative breast cancer patients
Presenter: Amaia Urrizola
Session: E-Poster Display
Resources:
Abstract
1031P - Tilsotolimod engages the TLR9 pathway to promote antigen presentation and type I IFN signaling in solid tumours
Presenter: Hani Babiker
Session: E-Poster Display
Resources:
Abstract